GET DAILY SIGNALSBio-Rad Laboratories (BIO) Posts Q3 Results with Modest Growth and EPS Beat
Key Takeaways
- Bio-Rad Laboratories reported third-quarter 2026 net sales of approximately $656.4 million, up 0.5% year over year and slightly above the consensus estimate of $649.95 million.
- Non-GAAP diluted earnings per share (EPS) came in at $2.65, up from $2.26 a year earlier and ahead of the roughly $2.23 consensus estimate.
- The company returned to currency-neutral revenue growth, driven by Clinical Diagnostics and continued strength in Droplet Digital PCR (ddPCR) instrument demand.
- GAAP results reflected a $50 million non-cash intangible asset impairment and restructuring charges, which pushed the quarter to an operating loss despite higher non-GAAP margins.
- Management reaffirmed its full-year 2026 outlook, including a non-GAAP operating margin target of 10% to 12%.
Why These Results Matter
Bio-Rad's third-quarter results matter because they offer a fresh read on two distinct end markets: life science research and clinical diagnostics. After a soft start to 2026 marked by academic funding constraints and Middle East disruption, investors have been watching for evidence that revenue can stabilize and margins can recover. The quarter's return to currency-neutral growth, combined with a sequential improvement in non-GAAP gross margin, suggests the company's transformation initiatives are beginning to show through. For a company that holds a significant equity stake in Sartorius AG, reported results can also swing sharply on mark-to-market moves, making the underlying operational performance the key signal for long-term holders. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The Quarter's Reported Figures
For the third quarter ended September 30, 2026, BIO reported net sales of approximately $656.4 million, a 0.5% increase from $653 million in the prior-year period. On a currency-neutral basis, sales rose 0.7%. Non-GAAP diluted EPS was $2.65, up from $2.26 a year earlier, while non-GAAP net income reached $72 million versus $61 million in the year-ago quarter.
Segment performance diverged. Clinical Diagnostics sales rose 2.7% to roughly $402 million, helped by order timing in quality systems and diabetes products. Life Science sales declined 2.8% to $255 million, pressured by lower process chromatography sales and ongoing academic research softness, though the ddPCR portfolio grew 7% on a currency-neutral basis with instrument revenue up more than 20%.
On a GAAP basis, the quarter included a $50 million intangible asset impairment and restructuring charges, contributing to a GAAP operating loss of roughly $50 million. Excluding these items, non-GAAP gross margin improved to 54.5% from 53.5% a year earlier.
Market Reaction and Investor Sentiment
The initial investor takeaway was constructive. A top-line beat, above-consensus EPS, and a return to currency-neutral growth supported a positive tone heading into the earnings call. The segment mix was the central narrative: steady Clinical Diagnostics demand and accelerating ddPCR instrument placements helped offset persistent weakness in process chromatography and academic research. Sentiment remains cautious, however, given the restructuring-related charges and the non-cash impairment, which highlight ongoing portfolio reprioritization. Investors will be weighing the durability of the recovery against management's acknowledgment that end markets remain uneven.
Forward Outlook and Key Factors to Monitor
Looking ahead, BIO reiterated its full-year 2026 guidance, expecting non-GAAP, currency-neutral revenue to range from a decline of roughly 3.0% to growth of 0.5%, alongside a non-GAAP operating margin of 10% to 12%. This framework implies continued variability across segments through the balance of the year.
A key factor to watch is ddPCR momentum. Strong instrument growth—up more than 20% year over year—is a leading indicator for future consumables pull-through, which typically follows installations within six to twelve months. If consumables demand recovers in biopharma and academia, it could provide a more durable lift to Life Science revenue.
Margin execution is another focus. Non-GAAP gross margin improved both year over year and sequentially, but restructuring costs and the intangible impairment weighed on reported results. Investors should monitor how quickly cost savings materialize and whether SG&A spending normalizes after this quarter's step-up.
Finally, watch the process chromatography business and regional dynamics, including academic funding trends in the Americas and demand signals in China. These areas have been the main sources of top-line drag, and any stabilization there would reinforce the case for a broader recovery. The company has not provided new long-term targets beyond its 2026 outlook, so guidance updates in future quarters will be closely scrutinized. From what I see, these factors will shape the trajectory into 2027.
Using Tickeron Tools for Ongoing Research
I’ve found Tickeron’s AI Screener helpful for quickly filtering life sciences names like BIO against peers on fundamentals and technical signals. It lets me scan for comparable setups and emerging patterns without spending hours on manual work, which keeps my process efficient when reviewing quarterly updates across the sector.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for BIO turns positive, indicating new upward trend
BIO saw its Momentum Indicator move above the 0 level on October 22, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 95 similar instances where the indicator turned positive. In 69 of the 95 cases, the stock moved higher in the following days. The odds of a move higher are at 73%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BIO's RSI Indicator exited the oversold zone, 19 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.
The Moving Average Convergence Divergence (MACD) for BIO just turned positive on October 23, 2026. Looking at past instances where BIO's MACD turned positive, the stock continued to rise in 37 of 51 cases over the following month. The odds of a continued upward trend are 73%.
BIO moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIO advanced for three days, in 194 of 299 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 64 cases where BIO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 70%.
The 10-day moving average for BIO crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
BIO broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BIO entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. BIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 87 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.397) is normal, around the industry mean (4.170). P/E Ratio (45.554) is within average values for comparable stocks, (1.500). Projected Growth (PEG Ratio) (4.006) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (3.940) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of life science research products and clinical diagnostics
Industry MedicalNursingServices
Advertisement